Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 17/20 | 0.47 |
| ▸ | JAK1 | P23458 | 17/20 | 0.47 |
| ▸ | TYK2 | P29597 | 17/20 | 0.47 |
| ▸ | JAK3 | P52333 | 17/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436567 | 1.00 | KMT2A (0.50) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL22121416 | 0.89 | KMT2A (0.57) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL19451470 | 0.84 | STING1 (0.48) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL28421225 | 0.84 | STING1 (0.48) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL29405998 | 0.84 | STING1 (0.48) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL20066406 | 0.84 | KMT2A (0.47) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL22151665 | 0.83 | KDM4E (0.55) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL21643845 | 0.81 | STING1 (0.42) | KMT2A | |
| SCHEMBL21643841 | 0.81 | STING1 (0.42) | KMT2A | |
| SCHEMBL27204002 | 0.81 | STING1 (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3691640-A1 | METHODS FOR ADMINISTERING STING AGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019069275-A1 | METHODS FOR ADMINISTERING STING AGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
| EP-3440076-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017175147-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |